Guideline Recommendations for Aspirin Therapy in Cardiovascular Prevention and Acute Coronary Syndromes

Secondary Prevention (Established ASCVD)

Class I recommendation (strong) from the ACC/AHA: Aspirin should be prescribed for all patients with documented atherosclerotic cardiovascular disease, including prior myocardial infarction, stroke/TIA, peripheral arterial disease, prior coronary or vascular bypass surgery, and documented angina. 1
Recommended dose: 75 – 162 mg daily (most U.S. clinicians use 81 mg). Evidence level: high‑quality guideline consensus. 3
Allergy alternative: In patients with aspirin hypersensitivity, clopidogrel 75 mg daily is advised as a substitute. Evidence level: guideline‑based recommendation. 3

Class IIb recommendation (may be considered) from the ACC/AHA: Aspirin may be used only when the individual has a ≥10 % 10‑year ASCVD risk (calculated with a validated risk estimator) and a low bleeding risk, with willingness for long‑term therapy. Evidence level: moderate (based on risk‑benefit analyses). 2
Dose for primary prevention: 75 – 100 mg daily (lower end preferred to limit bleeding). Evidence level: guideline consensus. 2

Class III recommendation (recommend against) from the ACC/AHA: Initiating aspirin for primary prevention is not advised because bleeding risk outweighs cardiovascular benefit in this age group. Evidence level: moderate. 2

Insufficient evidence to support aspirin for primary prevention in adults under 40; routine use is not recommended. Evidence level: low‑quality evidence. 2
Contraindication in persons < 21 years due to the risk of Reye syndrome. Evidence level: strong safety warning. 3

May be considered in diabetic patients who are ≥ 50 years (men) or ≥ 60 years (women) and have at least one additional major ASCVD risk factor (e.g., family history of premature ASCVD, dyslipidemia, chronic kidney disease or albuminuria). Evidence level: moderate (based on risk stratification). 5
Not recommended for diabetic patients > 70 years or for younger diabetics without additional risk factors, because bleeding risk exceeds benefit. Evidence level: moderate. 3

Do not prescribe aspirin in patients with any of the following (ACC/AHA & guideline societies):

The 2019 ACC/AHA guidelines list CAC as a risk‑enhancing factor that may inform aspirin decisions, though it is not mandatory. Evidence level: moderate. 2

Mandatory aspirin therapy for all ACS presentations (ACC/AHA Class I). Evidence level: high. 1
Loading dose: 162 – 325 mg chewable, non‑enteric coated aspirin for rapid absorption. Evidence level: high. 1
Maintenance dose: 75 – 100 mg daily, non‑enteric coated, continued indefinitely as secondary prevention. Evidence level: high. 1
Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) is required for at least 12 months after ACS. Evidence level: high. 3

Overuse in low‑risk populations (≤ 10 % 10‑year ASCVD risk or age ≥ 60) provides no net benefit and may cause harm. Evidence level: moderate. 2
Using doses > 100 mg daily increases bleeding without additional cardiovascular benefit. Evidence level: moderate. 1
Failure to assess bleeding risk (history of GI bleed, concurrent anticoagulants, age > 70, renal disease) before initiating aspirin leads to avoidable adverse events. Evidence level: moderate. 3
Assuming all diabetic patients need aspirin ignores the need for individualized risk assessment; only those meeting age and risk‑factor thresholds benefit. Evidence level: moderate. 3